Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
2022studies shown
Showing 1,951-1,975 of 2,022
TerminatedNCT03868839

Telmisartan Pilot Study on Treatment Resistant Schizophrenia

This study exists to see whether blood tests and biological markers is workable and worth testing more broadly. Researchers are trying to understand what blood tests and biological markers can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Xiaoduo Fan
Condition
Schizophrenia
CompletedNCT05262790

The Difference of Grey Matter Volume Among the Patients of Schizophrenia

This study exists to explore whether brain scans or other body measurements could improve care and understanding. Researchers are trying to understand whether brain scans or other body measurements can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
Global
Sponsor
Shanghai Mental Health Center
Condition
Schizophrenia
CompletedNCT05259748

The Effect of Psychoeducation on Healthy Lifestyle Behaviors in Individuals With Schizophrenia

This study exists to see whether psychoeducation, a guided learning and support program, can play a useful role in care. Researchers are trying to understand whether psychoeducation, a guided learning and support program, can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Turkey
Sponsor
Hatay Training and Research Hospital
Condition
Schizophrenia
CompletedNCT03920384

Improving Psychological Therapy for Psychosis: A Case Series

This study exists to explore whether cognitive behavioural therapy, a structured talking treatment, could improve care and understanding. Researchers are trying to understand whether cognitive behavioural therapy, a structured talking treatment, can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherOver 16 Years
Countries
United Kingdom
Sponsor
University of Edinburgh
Condition
Schizophrenia
CompletedNCT05258123

Ginkgo Biloba Extract in the Treatment of Schizophrenia

This study exists to explore whether questionnaires and follow-up reports could improve care and understanding. Researchers are trying to understand whether questionnaires and follow-up reports can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
China
Sponsor
Beijing HuiLongGuan Hospital
Condition
Schizophrenia
CompletedNCT03160521

Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia

This study exists to compare options and see whether a digital app or remote support tool offers something meaningfully different. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Ukraine, United States
Sponsor
Rovi Pharmaceuticals Laboratories
Condition
Schizophrenia
CompletedNCT05247151

The Association of Affective Resonance With Empathy Modulated by Negative Symptomatology and Oxytocin

This study exists to see whether cognitive behavioural therapy, a structured talking treatment, is workable and worth testing more broadly. Researchers are trying to understand whether cognitive behavioural therapy, a structured talking treatment, can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Germany
Sponsor
Charite University, Berlin, Germany
Condition
Schizophrenia
CompletedNCT00295139

Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients

This study exists to understand what helps a medication treatment work in everyday practice, not just under ideal conditions. Researchers are trying to understand whether a medication treatment can work better when mental health difficulties overlap with substance use.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
CompletedNCT03221270

Targeting Auditory Hallucinations With Alternating Current Stimulation

This study exists to explore whether brain scans or other body measurements could improve care and understanding. Researchers are trying to understand what brain scans or other body measurements can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 18 Years to 70 Years
Countries
United States
Sponsor
University of North Carolina, Chapel Hill
Condition
Schizophrenia
CompletedNCT00174265

6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)

This study exists to understand how the medication Asenapine holds up over time after the earliest research stage. Researchers are trying to understand how people respond to the medication Asenapine in practice and what may need to be adjusted.

SchizophreniaOtherOver 18 Years
Countries
Global
Sponsor
Organon and Co
Condition
Schizophrenia
CompletedNCT00281320

Study of Asenapine in Elderly Subjects With Psychosis (A7501021)(P05717)

This study exists to better understand the safety of the medication Asenapine and how manageable it feels in practice. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.

SchizophreniaOtherOver 65 Years
Countries
Global
Sponsor
Organon and Co
Condition
Schizophrenia
CompletedNCT01101464

A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)

This study exists to compare options and see whether a medication treatment offers something meaningfully different. Researchers are trying to understand what a medication treatment could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Global
Sponsor
Organon and Co
Condition
Schizophrenia
CompletedNCT00145496

Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)

This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand what a digital app or remote support tool could change in day-to-day care and decision-making.

SchizophreniaOtherOver 18 Years
Countries
Global
Sponsor
Organon and Co
Condition
Schizophrenia
CompletedNCT04013932

Family Psychoeducation for Adults With Psychotic Disorders in Tanzania

This study exists to see whether psychoeducation, a guided learning and support program, is workable and worth testing more broadly. Researchers are trying to understand whether psychoeducation, a guided learning and support program, can better prevent setbacks and support longer-term stability.

SchizophreniaOtherFrom 18 Years to 50 Years
Countries
Tanzania
Sponsor
Duke University
Condition
Schizophrenia
CompletedNCT02660775

Social Cognitive Assessment in Autism and Schizophrenia

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 45 Years
Countries
France
Sponsor
Hôpital le Vinatier
Condition
Schizophrenia
CompletedNCT05207319

Effects of Integrated Moral Reasoning Development Intervention for Management of Violence in Schizophrenia

This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 20 Years to 65 Years
Countries
Taiwan
Sponsor
I-Shou University
Condition
Schizophrenia
WithdrawnNCT04054973

L-arginine Study for Persistent Symptoms of Schizophrenia

This study exists to explore whether brain scans or other body measurements could improve care and understanding. Researchers are trying to understand what brain scans or other body measurements can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
University of Massachusetts, Worcester
Condition
Schizophrenia
CompletedNCT02417142

Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia

This study exists to compare options and see whether a therapy or guided support program offers something meaningfully different. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
University of Massachusetts, Worcester
Condition
Schizophrenia
CompletedNCT01012167

Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia

This study exists to compare options and see whether this type of care offers something meaningfully different. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 64 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
CompletedNCT03772951

The Efficacy of Computerized Cognitive Remediation Therapy for Chronic Schizophrenia

This study exists to see whether a therapy or guided support program can make care clearer and more responsive. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
China
Sponsor
Shanghai Mental Health Center
Condition
Schizophrenia